Inari Medical, Inc. is a medical device company headquartered in Redwood City, California, that focuses on the design, development and commercialization of innovative therapies for patients suffering from venous diseases. Since its founding in 2005, the company has concentrated on addressing the significant clinical challenges associated with blood clots in large veins and pulmonary arteries, which can lead to deep vein thrombosis (DVT) and pulmonary embolism (PE). Inari went public in October 2020 and trades on the NASDAQ under the ticker symbol NARI.
The company’s primary products are the FlowTriever and ClotTriever systems, both of which are catheter-based mechanical thrombectomy devices. The FlowTriever system is cleared by the U.S. Food and Drug Administration (FDA) for the treatment of pulmonary embolism, using a large-bore catheter to aspirate clot from the pulmonary arteries without the need for thrombolytic drugs. The ClotTriever system is designed to rapidly remove large clot burden from the peripheral veins for patients with DVT, restoring blood flow without the use of systemic clot-dissolving agents.
Inari Medical markets its products in the United States and has obtained CE mark approval for its systems in Europe, enabling commercial distribution in multiple countries across the region. The company has also established distribution channels in Canada, Australia and select markets in Asia. To support adoption, Inari provides comprehensive physician training programs, clinical support and procedural guidance to interventional radiologists, vascular surgeons and other specialists who perform thrombectomy procedures.
The leadership team is led by Mark H. Dorfman, co-founder and chief executive officer, who has guided the company’s growth from early research and development through its initial public offering. Under Dorfman’s direction, Inari continues to invest in clinical research and product enhancements, aiming to expand its pipeline of next-generation therapies for venous thromboembolism and related cardiovascular conditions.
AI Generated. May Contain Errors.
